These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16256398)

  • 1. Rheumatoid arthritis in 2005: which patients should receive TNFalpha antagonists and when? A point of view.
    Le Loët X; Lequerré T; Vittecoq O
    Joint Bone Spine; 2005 Dec; 72(6):447-50. PubMed ID: 16256398
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study.
    Batteux B; Devauchelle A; Boyard PL; Sejourné A; Fardellone P; Goëb V
    Joint Bone Spine; 2016 Oct; 83(5):607-9. PubMed ID: 26919803
    [No Abstract]   [Full Text] [Related]  

  • 3. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].
    Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S
    Reumatizam; 2007; 54(1):16-9. PubMed ID: 18450272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradoxical psoriatic arthritis in a patient with rheumatoid arthritis treated by TNFα blocker.
    Villani AP; Weiler L; Jullien D; Chapurlat R; Confavreux C
    Joint Bone Spine; 2014 Oct; 81(5):455-6. PubMed ID: 24561024
    [No Abstract]   [Full Text] [Related]  

  • 5. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].
    Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S
    Reumatizam; 2008; 55(1):22-5. PubMed ID: 19024266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).
    Ledingham J; Deighton C;
    Rheumatology (Oxford); 2005 Feb; 44(2):157-63. PubMed ID: 15637039
    [No Abstract]   [Full Text] [Related]  

  • 7. Access to disease modifying treatments for rheumatoid arthritis patients.
    Furst DE; Breedveld FC; Burmester GR; Crofford L; Emery P; Feldman M; Kalden JR; Kavanaugh A; Keystone E; Lipsky PE; Maini RN; Moreland L; Smolen JS; Van De Putte L; Vischer T; Weinblatt M; Weissman M
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I129-30. PubMed ID: 10577989
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of rheumatoid arthritis].
    Bolten WW
    MMW Fortschr Med; 2008 Aug; 150(32-35):50-3; quiz 54. PubMed ID: 19006884
    [No Abstract]   [Full Text] [Related]  

  • 9. [TNFalpha inhibitors for the treatment of rheumatoid arthritis].
    Sany J; Kaiser MJ
    Ann Med Interne (Paris); 2002 Feb; 153(1):34-40. PubMed ID: 11994688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comments on Falgarone et al. editorial entitled "TNFalpha antagonists in rheumatoid arthritis patients seen in everyday practice".
    Legoff P
    Joint Bone Spine; 2008 Oct; 75(5):626; author reply 626. PubMed ID: 18805723
    [No Abstract]   [Full Text] [Related]  

  • 11. [Stable remission of early active rheumatoid arthritis treated with etanercept (Enbrel)].
    Kaliterna DM
    Reumatizam; 2008; 55(2):60-1. PubMed ID: 19024277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again).
    Deighton CM; George E; Kiely PD; Ledingham J; Luqmani RA; Scott DG
    Rheumatology (Oxford); 2006 Jun; 45(6):649-52. PubMed ID: 16527881
    [No Abstract]   [Full Text] [Related]  

  • 13. Plasma cell mastitis in women with rheumatoid arthritis treated with TNFα antagonists: Report of 2 cases.
    Faccin M; Caillot O; Levêque J; Perdriger A
    Joint Bone Spine; 2016 Oct; 83(5):593-4. PubMed ID: 26774176
    [No Abstract]   [Full Text] [Related]  

  • 14. Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.
    Emery P; Van Vollenhoven R; Ostergaard M; Choy E; Combe B; Graninger W; Krueger K; Matucci-Cerinic M; Navarro F; van Riel P; Settas L; Steinfeld S
    Ann Rheum Dis; 2009 Apr; 68(4):456-9. PubMed ID: 19286904
    [No Abstract]   [Full Text] [Related]  

  • 15. Physico-chemical characteristics of TNFα blockers and their effectiveness in the treatment of rheumatoid arthritis: the theoretical and real worlds.
    Minota S
    Mod Rheumatol; 2013 Sep; 23(5):1034-6. PubMed ID: 22956242
    [No Abstract]   [Full Text] [Related]  

  • 16. Nonresponse to tumor necrosis factor antagonists--is there any point in re-treatment?
    Buch MH; Emery P
    Nat Clin Pract Rheumatol; 2006 Jun; 2(6):288-9. PubMed ID: 16932704
    [No Abstract]   [Full Text] [Related]  

  • 17. [TNF-alpha antagonists in therapy of rheumatoid arthritis].
    Gross WL; Gause A
    Z Rheumatol; 2003 Jun; 62(3):217. PubMed ID: 12931691
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of rheumatoid arthritis: we are getting there.
    Yazici Y
    Lancet; 2009 Jul; 374(9685):178-80. PubMed ID: 19560809
    [No Abstract]   [Full Text] [Related]  

  • 19. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.
    Fleischmann R; Shealy D
    Mol Interv; 2003 Sep; 3(6):310-8. PubMed ID: 14993463
    [No Abstract]   [Full Text] [Related]  

  • 20. Will our current success in treating rheumatoid arthritis hinder new drug development? That is the question!!
    Weinblatt ME
    Ann Rheum Dis; 2005 Nov; 64(11):1529-31. PubMed ID: 16126790
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.